Status:
TERMINATED
A Study To Assess the Effects Of PF-04457845 On BOLD fMRI In Subjects With Post Traumatic Stress Disorder
Lead Sponsor:
Pfizer
Conditions:
Post-Traumatic Stress Disorder
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
The purpose of the study is to evaluate proof of mechanism of PF-04457845, using a well-established neuroimaging paradigm including behavioral tasks selected to activate neuro-circuitry relevant to Po...
Detailed Description
This is a Phase II, randomized, placebo-controlled, parallel group design study in male and female subjects with moderate-to-severe Post Traumatic Stress Disorder between the ages of 18 and 60 years o...
Eligibility Criteria
Inclusion
- Men and women 18-60 years of age with a primary psychiatric diagnosis of Post Traumatic Stress Disorder
Exclusion
- Other psychiatric illness requiring current treatment with medication.
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2015
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT02216097
Start Date
October 1 2014
End Date
March 1 2015
Last Update
June 29 2016
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical and Translational Science Institute (CTSI)
New York, New York, United States, 10016
2
NYU CTSI Research Pharmacy (Drug Shipment Address)
New York, New York, United States, 10016
3
NYU School of Medicine
New York, New York, United States, 10016